At Alcon, our ocular health products for dry eye and ocular allergy, such as olopatadine hydrochloride ophthalmic solution, are designed, manufactured and marketed with a body of science developed through rigorous bench research and clinical studies. As the body of knowledge behind Alcon’s products grows, so does the challenge of making our customers aware of its depth. Our medical affairs organization is thus focused on both high-quality data generation and its communication to the clinical community.
High-quality scientific publications are essential to convey the clinical community’s knowledge and experience. This clinical science compendium provides a consolidated view of peer-reviewed publications for olopatadine hydrochloride, which is a dual-action agent (antihistamine/ mast cell stabilizer) that temporarily relieves itchy eyes due to pollen, ragweed, grass, animal dander and hair. This compendium primarily focuses on the 0.1% solution (Pataday ® Twice Daily Relief, formerly prescription Patanol®), the 0.2% solution (Pataday® Once Daily Relief, formerly prescription Pataday®), and the 0.7% solution (Pataday® Once Daily Relief Extra Strength, formerly prescription PAZEO®).
In addition to exploring this compendium, we encourage you to visit Alcon’s Medical Affairs website—AlconScience.com—to learn more about how medical science matters to us. Beyond scientific publications relating to Alcon’s portfolio, you will find more information on independent medical educational grants, teaching facility equipment placement, and areas of interest for investigator-initiated trials.